Summary of Ionis Pharmaceuticals FY Conference Call Company Overview - **Company**: Ionis Pharmaceuticals (NasdaqGS:IONS) - **Event**: 46th Annual TD Cowen Healthcare Conference - **Date**: March 02, 2026 Key Points Industry and Company Transformation - 2026 is anticipated to be a transformative year for Ionis, building on the momentum from 2025, which was also a significant year for the company [5][6] - Ionis transitioned from a research-focused entity to a fully integrated commercial biotechnology company, achieving two independent product launches: TRYNGOLZA for familial chylomicronemia syndrome (FCS) and DAWNZERA for hereditary angioedema (HAE) prophylaxis [5][6] Product Launches and Pipeline - **TRYNGOLZA**: - First FDA-approved medicine for FCS, launched successfully in 2025 [5] - Expected to expand into severe hypertriglyceridemia (sHTG) with a PDUFA date of June 30, 2026, representing a multibillion-dollar market opportunity [6][12] - **DAWNZERA**: - Launched in September 2025, with $8 million in revenue reported for the year [21] - Primarily attracting switch patients from existing therapies, particularly TAKHZYRO [25] Clinical Trials and Data Readouts - Anticipation of five phase 3 readouts from partnered pipelines in 2026, including successful results for bepirovirsen for chronic HBV [7] - New phase 3 trials planned for salanersen (spinal muscular atrophy) and sapablursen (polycythemia) [8] Financial Guidance and Revenue Expectations - Initial revenue guidance for TRYNGOLZA was $820-$825 million, which is expected to be revised upwards due to priority review status for sHTG [9][10] - Ionis aims to reduce net operating loss and provide detailed product-level revenue guidance in the upcoming Q1 earnings call [10] Pricing Strategy - Pricing for TRYNGOLZA is expected to be in the range of $10,000-$20,000 net price, with considerations for competitive pricing against a new entrant in the FCS space [17] - The company is focused on maximizing patient access while preserving value for stakeholders [13][17] Clinical Data and Safety Observations - Positive phase 3 data for triglyceride lowering in sHTG, showing over 70% reduction in triglycerides and 85% reduction in acute pancreatitis attacks [12][19] - Observations of a small increase in hepatic fat during treatment, which is not considered a toxicity and is expected to normalize over time [20] Future Studies and Market Potential - The CARDIO-TTRansform study is set to provide significant data on ATTR cardiomyopathy, with peak market sales for WAINUA expected to exceed $5 billion [36] - The study aims to demonstrate the benefits of combining silencer and stabilizer therapies, which could enhance treatment outcomes for patients [37][38] Angelman Syndrome Study - The phase 3 study for ION582 will focus on an 80-milligram dose, as long-term data indicated greater efficacy without safety concerns [46][47] - Enrollment is progressing well, with expectations to complete this year and report data next year [47][48] Additional Insights - The company is strategically managing the launch of DAWNZERA with a free drug program to facilitate patient access while navigating payer negotiations [23][24] - Ionis is committed to providing comprehensive data sets from ongoing studies, which will support its market positioning and product efficacy claims [40][41]

Summary of the Conference Call Company and Industry - **Company**: uniQure - **Industry**: Biotechnology, specifically focusing on gene therapies for neurodegenerative diseases such as Huntington's disease and epilepsy Key Points and Arguments Huntington's Disease and AMT-130 - **Phase 3 Data**: The pivotal Phase 1/2 trial for AMT-130 showed a 75% slowing of disease progression at three years, measured by the composite Unified Huntington's Disease Rating Scale (UHDRS) [10] - **Total Functional Capacity**: A 60% decline in disease progression was observed, which is significant for FDA approval [10] - **Neurofilament Light**: A decrease from baseline was noted, indicating reduced neurodegeneration, contrasting with the expected annual increase of 10%-15% [10] - **Patient Cohorts**: Data was pooled from 17 patients, with 12 having over three years of follow-up [3] - **FDA Interactions**: The FDA granted RMAT designation in early 2024 based on two-year data showing signals of slowing progression [16] - **BLA Submission**: The FDA expressed concerns about the Phase 1/2 study being hypothesis-generating and not pre-specifying statistical analyses, which affected the potential for BLA submission [28] - **Next Steps**: A Type B meeting with the FDA is planned to discuss Phase 3 study design and the use of external controls [53] Safety Profile - **Safety of AMT-130**: The procedure is reported to be remarkably safe, with no significant adverse events attributed to AMT-130 since December 2022 [72] - **Neuroinflammation**: Potential neuroinflammation is manageable with immune suppression, which will now be administered perioperatively [73] Regulatory Landscape - **International Engagement**: uniQure is engaging with regulators outside the U.S. for potential expedited reviews and expanded access pathways [75][78] - **Patient Advocacy**: Strong support from patient advocacy groups has been noted, with significant community involvement in lobbying for the therapy [86] Other Programs - **AMT-260 (Temporal Lobe Epilepsy)**: Early data showed a 92% reduction in seizure frequency in a case study, with ongoing trials expected to provide more data soon [87] - **AMT-191 (Fabry Disease)**: The program is in a Phase I/II study with 11 patients off enzyme replacement therapy, showing promising results [100][102] Financial Position and Partnerships - **Funding Strategy**: The company has a runway into the second half of 2029 and is disciplined in investment decisions, focusing on data that supports further investments [104][107] - **Partnerships**: Future partnerships will depend on data from existing programs and the Phase III strategy for Huntington's disease [107] Additional Important Information - **Ethical Considerations**: The company is considering the ethical implications of sham-controlled studies in slow-progressing diseases like Huntington's [61] - **Long-term Data**: The company plans to update the statistical analysis plan to include four-year assessments, which will provide further insights into treatment durability [66]

Summary of Incyte's Conference Call Company Overview - **Company**: Incyte - **Event**: 46th Annual TD Cowen Healthcare Conference - **CEO**: Bill Meury Key Points Business Segments and Growth Projections - Incyte's business is divided into three parts: core business excluding Jakafi, pipeline execution, and business development [2][4] - The core business excluding Jakafi is projected to grow from $1.2 billion in 2025 to approximately $1.7 billion by the end of 2026, with a target of $3 billion to $4 billion by 2030 [2] - Key growth products include Opzelura, Niktimvo, Monjuvi, povorcitinib, and XR [2] - The pipeline consists of 7 products in late-stage development, with estimated peak sales of around $10 billion [3] Opzelura Insights - Opzelura has a strong demand with 250,000 annual patients in the U.S. and a projected prescription volume increase of 15%-20% year-over-year [10] - Plans to expand the sales force and target audience in 2026 to drive growth [10] - The moderate atopic dermatitis (AD) indication in Europe could generate $200 million to $300 million in revenue over the next several years [12] - Expected data on Opzelura's use in hidradenitis suppurativa (HS) by the end of 2026, with potential revenue similar to AD or vitiligo [12] Oncology Portfolio - Monjuvi and Niktimvo are highlighted as key growth assets, with Monjuvi's frontline DLBCL study data expected in the second half of the year [13][14] - A modest market share of 10% in frontline DLBCL could double Monjuvi's annualized sales [13] - Niktimvo's second year is crucial for expanding its use beyond the fourth line of treatment [14] Pipeline Developments - The company is focused on advancing its pipeline, particularly with the 989 asset for essential thrombocythemia (ET) and myelofibrosis (MF) [23] - Positive data from ASH indicates a complete hematological response of over 80% for 989 in ET, compared to 25%-50% for hydroxyurea [23] - Plans to provide clarity on phase 3 programs for ET and MF by the first quarter earnings call [25][26] Business Development Strategy - Incyte aims to use business development to strengthen its core rather than fill revenue gaps [4] - Cost management is a priority, with SG&A expected to increase by only 4% in 2026 [4] XR Product Launch - XR is expected to launch later this year, offering a more convenient once-daily formulation compared to traditional Jakafi [18][20] - Targeting a conversion rate of 15%-20% from Jakafi to XR, which will serve as a bridge to future growth [21] Competitive Landscape - Povorcitinib is positioned as a unique oral treatment for HS, with no FDA-approved oral options currently available for moderate to severe cases [53] - The drug's efficacy in itch relief and flare control is comparable to biologics, with a focus on pre-biologic treatment settings [54] G12D Inhibitor Development - Incyte's G12D inhibitor is noted for its high selectivity and potential to combine with standard chemotherapy [56] - The goal is to complete phase 3 trials demonstrating a progression-free survival (PFS) of approximately 9 months [56] Additional Insights - The company is committed to maintaining a strong pipeline and addressing unmet medical needs in hematological conditions [45] - The potential for 989 to become a standard of care in ET is emphasized, particularly for CALR mutation patients [46] This summary encapsulates the key insights and projections discussed during the conference call, highlighting Incyte's strategic focus on growth, pipeline development, and market positioning.

Summary of uniQure FY Conference Call - March 02, 2026 Company Overview - **Company**: uniQure (NasdaqGS:QURE) - **Focus**: Gene therapies for neurodegenerative diseases, particularly Huntington's disease and epilepsy Key Points on Huntington's Disease Program (AMT-130) - **Phase 3 Data**: The pivotal phase 1/2 trial showed a 75% slowing of disease progression at three years, measured by the composite Unified Huntington's Disease Rating Scale (UHDRS) [9] - **Total Functional Capacity**: A 60% decline in disease progression was observed, which is significant for FDA approval [9] - **Neurofilament Light**: A decrease from baseline was noted, contrasting with the expected 10%-15% annual increase in neurodegeneration markers [9] - **FDA Interactions**: The FDA granted RMAT designation in early 2024 based on initial data, but later expressed concerns about the Phase 1/2 study being hypothesis-generating and not suitable for BLA submission [15][20] - **Next Steps**: A Type B meeting with the FDA is planned to discuss phase 3 study design and the use of external controls [44][46] - **Patient Community Support**: Strong advocacy from patient groups has been noted, with significant engagement in policy discussions and petitions to the FDA [82][84] Key Points on AMT-260 (Temporal Lobe Epilepsy Program) - **Initial Data**: A case study showed a 92% reduction in seizure frequency in the first patient treated, with no significant adverse events reported [84] - **Current Status**: Six patients have been dosed in the first cohort, with data expected in the second quarter of 2026 [85] - **Future Goals**: Aiming for a 50% or higher reduction in seizures to support progression to pivotal trials [96] Key Points on AMT-191 (Fabry Disease Program) - **Study Progress**: A Phase I/II study is ongoing with 11 patients treated, all of whom are off enzyme replacement therapy [99] - **Outcomes**: Dose-dependent increases in the deficient enzyme have been observed, with ongoing monitoring for long-term outcomes [99] Financial and Strategic Considerations - **Funding Position**: The company has a strong balance sheet with a runway into the second half of 2029, allowing for continued investment in promising programs [104] - **Partnership Strategy**: The company remains open to partnerships but emphasizes the need for data to support investment decisions [105] Safety Profile - **AMT-130 Administration**: The procedure is reported to be safe and well-tolerated, with most adverse events being procedure-related rather than drug-related [64] Regulatory Landscape - **International Engagement**: The company is engaging with regulators outside the U.S. for potential expedited reviews and expanded access pathways [71][74] Conclusion - **Commitment to Patients**: The company is focused on advancing its therapies while ensuring ethical considerations in study designs, particularly for slow-progressing diseases like Huntington's [46][54]

Summary of Jade Biosciences FY Conference Call Company Overview - **Company**: Jade Biosciences (NasdaqCM:JBIO) - **Focus**: Biotech company specializing in autoimmune diseases, spun out of Paragon Therapeutics with three licensed assets [2][3] Key Programs 1. **JADE101**: - **Target**: Anti-APRIL for IgA nephropathy (IgAN) - **Market Size**: Estimated at $10 billion, potentially understated due to new KDIGO guidelines allowing broader treatment [3][4] - **Clinical Data**: Interim phase 1 data expected in the first half of 2026 [2][3] - **Mechanism**: Designed for best-in-class attributes, including high binding affinity and extended half-life [4][10] - **Efficacy Goals**: Aim for maximal APRIL suppression with fewer than 6 injections per year [7][14] - **Clinical Remission**: 26% of patients achieved clinical remission in trials, significantly higher than 12% in previous studies [9] 2. **JADE201**: - **Target**: Afucosylated anti-BAFF-R for rheumatoid arthritis (RA) - **Clinical Trial**: Phase 1 study to begin in Q2 2026, with data expected in 2027 [20][21] - **Mechanism**: Designed to overcome B-cell rebound seen in current therapies, with dual mechanisms for enhanced efficacy [16][17] 3. **JADE301**: - **Status**: Lead candidate nominated, target to be disclosed in the second half of 2026, approximately one year behind JADE201 [3][23] Market Dynamics - **KDIGO Guidelines**: New guidelines favoring anti-APRIL therapies are expected to enhance market opportunities [6][9] - **Competitive Landscape**: Key competitors include Sibeprylimab and Atacicept, with JADE101 showing superior binding affinity [13][14] - **Patient Population**: Approximately 150,000 to 200,000 patients in the U.S. with IgAN, with 60%-75% requiring therapy [5][6] Financials - **Cash Position**: Ended 2025 with approximately $336 million, providing a runway into the first half of 2028 [23] Safety and Efficacy Considerations - **Immunogenicity**: Monitoring for anti-drug antibodies (ADAs) is crucial, as seen in previous studies where 30% of patients developed ADAs [37][38] - **Safety Profile**: Previous studies showed an unremarkable safety profile, but ongoing monitoring for infection rates and hypogammaglobulinemia is essential [38][43] Future Outlook - **Regulatory Pathway**: Plans to engage with the National Kidney Foundation to discuss potential expedited pathways for registration [47][51] - **Market Potential**: Significant opportunities in rheumatology and nephrology, with a focus on high unmet needs [55][56] Underappreciated Aspects - **Pipeline Potential**: While JADE101 is the primary focus, the broader pipeline and the expertise of the team are seen as underappreciated by investors [58][59] This summary encapsulates the key points discussed during the conference call, highlighting Jade Biosciences' strategic focus, clinical programs, market dynamics, and future outlook.

Nautilus Biotechnology (NasdaqGS:NAUT) FY Conference March 02, 2026 10:30 AM ET Company ParticipantsSujal Patel - Co-Founder and CEOConference Call ParticipantsDan Brennan - Life Science Tools and Diagnostics AnalystDan BrennanGood morning. Dan Brennan, TD Cowen Life Science Tools and Diagnostics Analyst. Day one of the 46th annual TD Cowen Healthcare Conference. Pleased to be joined here on the stage with Co-founder and CEO of Nautilus, Sujal Patel. Sujal, welcome and thank you.Sujal PatelThanks, Dan, and ...

Summary of Haemonetics Conference Call Company Overview - **Company**: Haemonetics - **Industry**: Medical Technology (MedTech) - **Revenue**: Approaching $1.4 billion, diversified small midcap MedTech company - **Market Leadership**: Global leader in plasma apheresis with a billion-dollar addressable market [2][3] Key Financial Performance - **Fiscal Year Performance**: - High single-digit revenue growth - Operating margin expansion of over 800 basis points - Cumulative free cash flow of $600 million to $700 million - Added $3 in earnings per share over the four-year long-range plan (LRP) [3] Plasma Business Insights - **Growth**: Plasma segment grew 3% organically, 20% excluding CSL [4] - **Drivers of Growth**: - Sustained share gains - Innovation-led platform benefits - Increased collection strength [5] - **Persona PLUS Launch**: - Mid-single digit yield increase compared to Persona - Built on data-driven approach with a pivotal trial involving over 30,000 plasma donations [6][8] Customer Relationships and Market Position - **Customer Engagement**: Strong relationships leading to share gains and deeper strategic partnerships [10] - **Market Leadership**: Expectation to grow global marketplace leadership for the foreseeable future [12] Competitive Landscape - **Competitors**: Mention of Terumo's Rika and other competitors, with emphasis on Haemonetics' integrated platform and lower cost metrics [13][14] - **NexSys and Persona PLUS**: Positive reception from customers, leading to standardization around Haemonetics' technology [10] Interventional Technologies and Vascular Closure - **Challenges**: Acknowledgment of challenges in the vascular closure space but confidence in returning to above-market growth [19][20] - **Market Dynamics**: Shift to Ambulatory Surgical Centers (ASCs) and increased adoption of PFA expected to favor Haemonetics [21] - **Product Launches**: - MVP label expansion in the U.S. and Japan - Vivasure acquisition leading to the launch of PerQseal Elite [21][27] Blood Management Technologies - **Growth Potential**: Blood management technologies, particularly TEG, showing consistent double-digit growth with significant market penetration opportunities [33][34] - **Market Size**: Global Serviceable Available Market (SAM) for TEG estimated at over $400 million, with less than 50% penetration [34] Capital Deployment Strategy - **Focus on Organic Growth**: Prioritizing R&D and commercial execution for competitive advantage [43] - **Debt Management**: Addressed $300 million debt maturity using revolver, maintaining capital structure efficiency [44] - **Share Repurchases**: Attractive risk-adjusted returns at current share prices, with plans for opportunistic capital deployment [44] Margin Improvement - **Current Margins**: Operating income margin increased from 13% to 26% over the past decade, with aspirations for further improvement [48][49] - **Future Expectations**: Anticipation of continued margin expansion driven by operational improvements and product mix [49] Outlook for FY27 - **Growth Expectations**: Balanced, sustainable growth with continued revenue growth, margin expansion, and free cash flow [53] Conclusion - **Company's Position**: Haemonetics is positioned for future growth with a strong focus on innovation, customer relationships, and market leadership in plasma and blood management technologies [55]

Summary of Raymond James Financial FY Conference Call Company Overview - **Company**: Raymond James Financial (NYSE:RJF) - **Date of Conference**: March 02, 2026 Core Industry Insights - **Industry Context**: The financial services industry is highly competitive, with firms often claiming to prioritize client interests. However, many firms have faced challenges due to internal risk-taking unrelated to client needs, particularly during financial crises [3][4][6]. Key Points and Arguments 1. **Client-First Philosophy**: Raymond James emphasizes a client-first approach, distinguishing itself from competitors who engage in risky financial practices for their own benefit [4][5]. 2. **Long-Term Focus**: The company prioritizes long-term decision-making over short-term gains, aiming for sustainable growth and cultural preservation during acquisitions [5][9]. 3. **Financial Performance**: The company reported its fifth consecutive year of record revenues and earnings, achieving a 12% compound annual growth rate in revenues over the past five years [21][22][23]. 4. **Operating Leverage**: Raymond James has successfully increased operating leverage, with a 21% increase in pre-tax income alongside revenue growth [22][23]. 5. **Capital Strength**: As of December 31, 2025, the company had a total capital ratio exceeding 24%, with $2.4 billion in excess Tier 1 capital and $2.1 billion in excess liquidity [24][25]. 6. **Investment in Technology**: The company is investing over $1 billion annually in technology, including cybersecurity and AI solutions, to enhance service delivery and operational efficiency [11][16][18][20]. 7. **Acquisition Strategy**: Raymond James focuses on cultural fit and mutual improvement in its acquisition strategy, ensuring that any target enhances both parties [27][28]. 8. **Dividend Policy**: The company maintains a target dividend payout ratio of 20%-30%, recently increasing its common stock dividend by 8% [29]. 9. **Risk Management in Private Credit**: The company remains cautious about private credit offerings, monitoring the market for potential risks while maintaining a conservative approach [33][34]. Additional Important Insights - **Personal Relationships**: The firm aims to differentiate itself by fostering deeply personal relationships with clients, which is increasingly rare in the industry [12][13]. - **Collaboration vs. Cross-Selling**: Raymond James distinguishes between collaboration (enhancing client relationships) and cross-selling (meeting quotas), emphasizing quality service over sales targets [35][36][37]. - **AI Integration**: The company is piloting an AI solution named Ray, designed to improve client service and operational efficiency, addressing the industry's need for technology-driven solutions [18][19]. This summary encapsulates the key insights and strategic directions discussed during the conference, highlighting Raymond James Financial's commitment to client service, long-term growth, and technological advancement in the financial services sector.

Summary of Revolve's Conference Call Company Overview - **Company Name**: Revolve - **Industry**: Fashion retail, specifically focusing on apparel, footwear, beauty, and accessories - **Business Model**: Digitally native and multi-branded, operating primarily online with two segments: Revolve (86% of business) and FWRD (14% of business) [1][2][4] Core Insights and Arguments - **Market Opportunity**: The domestic fashion market is over $700 billion, with a global market size of $3.3 trillion. Revolve currently has 20% of its business from international markets, indicating significant growth potential [3][4] - **Growth Metrics**: In 2025, Revolve achieved over $1.2 billion in revenue, with a net income growth of 9% CAGR over six years. The company has a strong focus on free cash flow and adjusted EBITDA, which has led to market share gains [5][6] - **Customer Engagement**: Revolve has a high customer retention rate of 89%, with 56% of active customers being repeat buyers, contributing to 83% of net sales. The company maintains a full-price sales mix of 82% [7][8] - **Technology and AI Utilization**: Revolve leverages AI for data-driven merchandising, customer experience enhancement, and operational efficiencies. This includes developing proprietary search algorithms and optimizing supply chain logistics [10][11][40][42] Financial Performance - **Recent Results**: Q4 2025 showed double-digit top-line growth with a 44% increase in adjusted EBITDA year-over-year. The company reported a 10% growth acceleration from Q3 to Q4 [13][14] - **Margin Goals**: Revolve aims for a double-digit EBITDA margin, currently at 8%. This will be achieved through gross margin expansion, primarily driven by own brands, and G&A leverage [29][30] Strategic Initiatives - **Expansion Plans**: Revolve plans to invest in physical retail, with recent openings in Aspen and The Grove. The company sees a significant opportunity in physical retail, as 60% of fashion retail sales still occur in-store [16][26] - **Product Diversification**: The company aims to broaden its product offerings beyond dresses, which currently make up 30% of the business. There are plans to expand into beauty and men's categories [19][20][21] - **International Growth**: Currently, international sales account for 21% of the business, with plans to enhance the customer experience in regions like China and the Middle East [22][23] Market Context - **Luxury Sector Dynamics**: The luxury market has seen turmoil with several competitors facing bankruptcy. Revolve views this as an opportunity to capture market share, particularly through its FWRD segment, which has seen 14% year-over-year sales growth [17][36] - **Own Brands Strategy**: Own brands currently represent 20% of the business, with potential to grow significantly. These brands offer higher gross margins and are exclusive to Revolve [24][25][34] Additional Insights - **Customer Experience Focus**: Revolve emphasizes a customer-first approach, offering free shipping and returns to replicate the physical shopping experience [7][8] - **Retail Expansion Caution**: While there is strong interest in expanding physical retail, the company is taking a cautious approach to ensure sustainable growth [44][46] This summary encapsulates the key points discussed during the conference call, highlighting Revolve's strategic direction, financial performance, and market opportunities.

Summary of Plexus Conference Call Company Overview - **Company**: Plexus - **Industry**: Electronic Manufacturing Services (EMS) - **Market Focus**: Healthcare life sciences, industrial, aerospace, and defense - **Company Size**: Approximately $4 billion in revenue - **Financial Goals**: Targeting annual revenue growth of 9%-12%, operating margin of 6% or greater (non-GAAP), and 15% return on invested capital [4][4][4] Core Insights and Arguments - **Market Dynamics**: - Plexus is experiencing a recovery from two years of flat growth, with positive trends in semiconductor capital equipment, healthcare, defense, and commercial space [11][12] - Commercial aerospace is still recovering, with expectations for future growth as Boeing and other aerospace companies ramp up production [12][12] - **Capacity Expansion**: - Recent investments include a new facility in Penang, Malaysia, which is expected to support up to $1 billion in revenue with a break-even point anticipated soon [19][19] - Expansion in Thailand is also underway, with rapid growth expected [19][19] - **Supply Chain Management**: - Plexus is focusing on regional production to shorten supply chains, with a strong presence in North America, Mexico, Asia, and Europe [27][27] - The company is actively managing component price fluctuations through a cost-plus model, ensuring that price increases are passed on to customers [58][58] - **Technological Investments**: - Investments in automation, such as the AutoStore unit, are expected to improve efficiency and margins [40][40] - AI is being deployed to enhance internal processes, including procurement and inventory management, leading to significant time savings [49][50] Additional Important Points - **Financial Performance**: - The company generated approximately $500 million in free cash flow over the past two fiscal years, with a target of $100 million in free cash flow for fiscal 2026 [101][101] - The cash cycle is being targeted to be in the mid-60s, with a current healthy balance sheet and a debt to EBITDA ratio below 1 [103][103] - **Shareholder Returns**: - Plexus has a $100 million share repurchase program, with $63 million remaining on the current authorization [117][117] - **Engineering Focus**: - Engineering is core to Plexus's operations, allowing for strong customer engagement and product development, particularly in aerospace and defense sectors [81][81][90] - **Growth Potential**: - The defense and unmanned systems market has the potential to double by fiscal 2026, driven by early engagement in upcoming programs [74][74] - The industrial sector, particularly semiconductor capital equipment, is expected to benefit from increased spending and AI advancements [75][75] This summary encapsulates the key points discussed during the Plexus conference call, highlighting the company's strategic focus, market dynamics, and financial performance.